

(Published in Part II, Section 3, Sub Section (ii) of the Gazette of India Extraordinary)

Government of India  
Ministry of Chemicals and Fertilizers  
Department of Pharmaceuticals  
National Pharmaceuticals Pricing Authority

New Delhi, the 25<sup>th</sup> October, 2023

ORDER

S.O. 4662(E):- Whereas the National Pharmaceutical Pricing Authority (NPPA) was established vide the Resolution of the Government of India in the Ministry of Chemicals and Fertilizers No. 33/7/97-Pl.I dated 29th August, 1997, inter-alia, to fix prices and notify the changes therein, if any, of bulk drugs and formulations, monitor the prices of non-scheduled drugs and formulations and oversee the implementation of the provisions of the Drugs (Price Control) Order (DPCO).

2. And whereas the Ministry of Chemicals and Fertilizers vide S.O.1394 (E) dated the 30th May, 2013, in exercise of the powers conferred by Section 3 and 5 of Essential Commodities Act, 1955 has delegated the powers in respect of specified paras of the DPCO, 2013, including para 32 of the said order to be exercised by the NPPA on behalf of the Central Government.

3. And whereas an application received from **M/s Cadila Pharmaceuticals Limited**, for exemption from the provisions of DPCO, 2013 under para 32 (i) & 32(ii) of the said order in respect of the formulation "**Cholecalciferol Aqueous Injection 6,00,000 IU/2ml (Vitamin D3 Injection)**" which was duly approved by the Office of Central Drugs Standard Control Organisation (India) as 'new drug' under the Drugs and Cosmetics Act, 1940 and Rules thereunder. Further, the Patent Office, Government of India has granted Patent to **M/s Cadila Pharmaceuticals Limited** for an invention entitled "**AN AQUEOUS PARENTERAL COMPOSITION OF VITAMIN D3**" for the term of 20 years from 3<sup>rd</sup> February 2018 in accordance with the provisions of the Patents Act, 1970(Patent No. 431119 and Date of Grant: 04.05.2023).

4. And whereas the NPPA at its **117<sup>th</sup> meeting dated 13.10.2023** noted that **M/s Cadila Pharmaceuticals Limited** meets the requirement of Para 32(i) & 32(ii) of DPCO 2013 and decided that exemption may be granted to **M/s Cadila Pharmaceuticals Limited** under Para 32(i) & 32 (ii) of DPCO, 2013 for their formulation "**Cholecalciferol Aqueous Injection 6,00,000 IU/2ml (Vitamin D3 Injection)**".

5. Now, therefore, in exercise of the powers delegated under para 32 of the Drugs (Prices Control) Order, 2013 vide S.O. 1394(E) dated 30th May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, **M/s Cadila Pharmaceuticals Limited** is exempted from the provisions of DPCO, 2013 under para 32(i) & 32 (ii) of the said order in respect of the formulation "**Cholecalciferol Aqueous Injection 6,00,000 IU/2ml (Vitamin D3 Injection)**" for a period of five years from the date of commencement of its commercial marketing by the manufacturer in the country or expiry of the Indian patent, whichever may be earlier.

6. **M/s Cadila Pharmaceuticals Limited** shall inform NPPA, the date of commercial marketing of the formulation "**Cholecalciferol Aqueous Injection 6,00,000 IU/2ml (Vitamin D3 Injection)**" in the country and the Price to Retailer (PTR) and Maximum

Retail Price fixed by the company in respect of above said formulation by issuing a price list in Form V under DPCO, 2013.

7. **M/s Cadila Pharmaceuticals Limited** shall also seek retail price approval for the formulation “**Cholecalciferol Aqueous Injection 6,00,000 IU/2ml (Vitamin D3 Injection)**”, if applicable, three month before the expiry of the exemption granted under Para 32(i)& 32 (ii) of DPCO 2013

PN/249/117/2023/F

F. No. 8(117)/2023/ DP/Div-II/NPPA

(Mahaveer Saini)  
Deputy Director (Pricing)